Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening by Ng, EKO et al.
Title
Differential expression of microRNAs in plasma of patients with
colorectal cancer: A potential marker for colorectal cancer
screening
Author(s) Ng, EKO; Chong, WWS; Jin, H; Lam, EKY; Shin, VY; Yu, J; Poon,TCW; Ng, SSM; Sung, JJY
Citation Gut, 2009, v. 58 n. 10, p. 1375-1381
Issued Date 2009
URL http://hdl.handle.net/10722/92202
Rights Creative Commons: Attribution 3.0 Hong Kong License
Differential expression of microRNAs in plasma of
patients with colorectal cancer: a potential marker
for colorectal cancer screening
E K O Ng,1 W W S Chong,1,2 H Jin,1 E K Y Lam,1 V Y Shin,1,2 J Yu,1,2 T C W Poon,1,2
S S M Ng,1,3 J J Y Sung1,2
See Commentary, p 1318
c Two supplementary tables
and a figure are published online
only at http://gut.bmj.com/
content/vol58/issue10
1 Institute of Digestive Disease,
Li Ka Shing Institute of Health
Sciences, The Chinese
University of Hong Kong, China;
2 Department of Medicine and
Therapeutics, The Chinese
University of Hong Kong, China;
3 Department of Surgery, The
Chinese University of Hong
Kong, China
Correspondence to:
Dr J J Y Sung, Institute of
Digestive Disease, The Chinese
University of Hong Kong, Prince
of Wales Hospital, Shatin, New
Territories, Hong Kong SAR,
China; joesung@cuhk.edu.hk
Revised 6 December 2008
Accepted 6 January 2009
Published Online First
9 February 2009
ABSTRACT
Objective: MicroRNAs (miRNAs) have been shown to
offer great potential in the diagnosis of cancer. We
investigated whether plasma miRNAs could discriminate
between patients with and without colorectal cancer
(CRC).
Methods: This study was divided into three phases:
(1) marker discovery using real-time PCR-based miRNA
profiling on plasma, corresponding cancerous and
adjacent non-cancerous colonic tissues of five patients
with CRC, along with plasma from five healthy individuals
as controls; (2) marker selection and validation by real-
time quantitative RT-PCR on a small set of plasma; and
(3) independent validation on a large set of plasma from
90 patients with CRC, 20 patients with gastric cancer, 20
patients with inflammatory bowel disease (IBD) and 50
healthy controls.
Results: Of the panel of 95 miRNAs analysed, five were
upregulated both in plasma and tissue samples. All the
five miRNAs were validated on the plasma of 25 patients
with CRC and 20 healthy controls. Both miR-17-3p and
miR-92 were significantly elevated in the patients with
CRC (p,0.0005). The plasma levels of these markers
were significantly reduced after surgery in 10 patients
with CRC (p,0.05). Further validation with an indepen-
dent set of plasma samples (n = 180) indicated that miR-
92 differentiates CRC from gastric cancer, IBD and normal
subjects. This marker yielded a receiver operating
characteristic curve area of 88.5%. At a cut-off of 240
(relative expression in comparison to RNU6B snRNA), the
sensitivity was 89% and the specificity was 70% in
discriminating CRC from control subjects.
Conclusion: MiR-92 is significantly elevated in plasma of
patients with CRC and can be a potential non-invasive
molecular marker for CRC screening.
Colorectal cancer (CRC) is the third most common
cancer worldwide with an estimated one million
new cases and a half million deaths each year.1
Screening for CRC allows early-stage diagnosis of
the malignancy and potentially reduces mortality
of the disease.2 Although colonoscopic screening
for CRC is currently the most reliable screening
tool, the invasive nature and the cost incurred have
hampered the wide application of this procedure.
On the other hand, the faecal occult blood test
(FOBT) has the limitation of low sensitivity and
requires meticulous dietary restriction.3 Thus,
there is a pressing need for new non-invasive
biomarkers to improve the detection of CRC.
Recently, the discovery of small (19–26 nucleo-
tides) non-protein-coding RNAs, so-called
microRNAs (miRNAs) that play important roles
in oncogenesis, has opened new opportunities of a
non-invasive test for the early diagnosis of cancer.4–6
Studies have shown that profiles of miRNA expres-
sion differ between normal tissue and tumour
tissues and vary among tumour types.5 7 Evidence
suggests that miRNA expression profiles can cluster
similar tumour types together more accurately than
the expression profiles of protein-coding mRNA
genes.7 Furthermore, miRNA expression signatures
have been used to predict prognosis.8–10 Since 1999,
tumour-associated RNAs have been detected in the
serum or plasma from patients suffering from breast,
colon and nasopharyngeal cancers.11–15 More
recently, several reports also suggest that cell-free
circulating miRNAs existed in serum and plasma.16–19
Accordingly, it raises the possibility of using
miRNAs as novel non-invasive molecular markers
for cancer detection. In the present study, we
evaluated the feasibility of using plasma miRNAs
as a non-invasive diagnostic test for CRC.
PATIENTS AND METHODS
Study design and patient samples
This study was divided into three phases: phase I,
marker discovery; phase II, marker selection and
validation; and phase III, large-scale validation.
Phase I: marker discovery
In this phase, pre-operative plasma, primary
cancerous biopsies and their adjacent non-cancer-
ous colonic tissues from five patients with CRC
were collected. Plasma from five age-matched
healthy subjects was collected as the control.
MicoRNA profiles were generated from the follow-
ing samples: (1) CRC plasma, (2) normal plasma,
(3) CRC tissues, and (4) adjacent normal tissues.
By comparing miRNA profiles from CRC plasma
versus normal plasma and CRC tissues versus
adjacent normal tissues, two differential miRNA
expression patterns were established and then
compared. Upregulated miRNAs in both plasma
and tissues were identified for further analysis in
phase II.
Phase II: marker selection and validation
Plasma samples were collected from 25 patients
with CRC before undergoing endoscopy. Plasma
from 20 healthy subjects was collected as normal
control. Putative miRNA markers identified in
phase I were verified on these plasma samples
from 25 patients with CRC and 20 controls.
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Plasma from another 10 patients with CRC was collected before
and 7 days after surgical resection. Markers proceeding to phase
III validation had to be significantly elevated in the 25 patients
with CRC and reduced after tumour resection.
Phase III: large-scale validation
Plasma was collected from an independent group of 90 patients
with CRC before endoscopy. Plasma from a set of 50 healthy
subjects was collected as the control. Putative markers identified
from phase II were verified on these independent sets of plasma
samples. Plasma from 20 patients with inflammatory bowel
disease (IBD) and 20 patients with gastric cancer (GC) was also
included to examine the specificity of the makers.
Informed consent was obtained from participants for the use
of their blood and tissue samples in this study. All patients were
considered sporadic cases on the basis that no family histories of
CRC were reported. Tumours were staged according to the
tumour–node–metastsis (TNM) staging system.20 No patient
received chemotherapy or radiotherapy before blood sampling.
Samples processing and microRNA extraction
Total RNA was extracted from tissues using miRNeasy Mini Kit
(Qiagen, Hilden, Germany) following the manufacturer’s
instructions. EDTA blood was centrifuged at 1600 g for
10 min at 4uC, and plasma was transferred to new tubes
followed by further centrifugation at 16 000 g for 10 min at
4uC. Total RNA containing small RNA was extracted from
500 ml of plasma using Trizol LS reagent (Invitrogen, Carlsbad,
California, USA) and miRNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol with the
following modifications: Trizol LS reagent was added to plasma
samples in volumetric ratios as previously described.14 21 After
phase separation by chloroform addition and centrifugation, 1.5
volumes of 100% ethanol was added to the aqueous phase and
the mixture was loaded into miRNeasy column (Qiagen)
according to the manufacturer’s instructions. DNase treatment
(Qiagen) was carried out to remove any contaminating DNA.
The final elution volume was 30 ml. The concentrations of all
RNA samples were quantified by NanoDrop 1000 (Nanodrop,
Wilmington, Delaware, USA). The concentration of RNA
extracted from plasma ranged from 4.8 to 23.9 ng/ml.
MicroRNA profiling of plasma and biopsy tissues
Plasma and biopsies from five patients with CRC (three male,
two female; age, 65 (SD 9.0) years) and plasma from five sex-
and age-matched healthy subjects (age, 62 (SD 6.4) years) were
used for miRNA profiling.
Profiling was performed using Cancer MicroRNA Array with
QuantiMir system (System Biosciences, Mountain View,
California, USA) which is a real-time PCR-based array contain-
ing a panel of 95 cancer-related miRNA assays and the U6
transcript as a normalisation signal. Briefly, 100 ng of total RNA
extracted from plasma and tissue samples was polyadenylated
by poly(A) polymerase and then reverse transcribed to cDNA.
Real-time qPCR was performed using Power SYBR Master Mix
(Applied Biosystems, Foster City, California, USA) using
miRNA-specific primers provided by the manufacturer in ABI
PRISM 7500 Real-time PCR system (Applied Biosystems). The
cycle threshold (Ct) is defined as the number of cycles required
for the fluorescent signal to cross the threshold in qPCR. DCt
was calculated by subtracting the Ct values of U6 from the Ct
values of the miRNA of interest. DDCt was then calculated by
subtracting DCt of the control from DCt of disease. Fold change
Table 1 Patient characteristics for plasma miRNA analysis
Characteristic
Patients with CRC (n = 130)
Healthy
controls
(n = 75)
Patients
with IBD
(n = 20)
Patients
with GC
(n = 20)
No of patients
No of
patients
No of
patients
No of
patients
Age (years)
Mean 71 69 71 68
Median (range) 73 (42–91) 70 (45–85) 73 (61–80) 72 (50–86)
Gender
Male 68 39 10 8
Female 62 36 10 12
TNM stage in
miRNA profiling (n = 5)
–
III 4 – – –
IV 1 – – –
TNM stage in
pre- and post-Op study (n = 10)
II 1 – – –
III 7 – – –
IV 2 – – –
TNM stage in
selected marker validation (n = 25)
– –
III 5 – – –
IV 20 – – –
TNM stage in
large-scale validation (n = 90)
I 6 – – –
II 34 – – –
III 23 – – –
IV 27 – –
CRC, colorectal cancer; GC, gastric cancer; IBD, inflammatory bowel disease; TNM, tumour–node–metastsis staging system.
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of gene was calculated by the equation 22DDCt. Most of the
miRNAs chosen for the array have been characterised with
regard to potential roles in cancer, cell development, and
apoptosis. The details describing the platform and selection of
miRNAs can be obtained from http://www.systembio.com
(accessed 22 April 2009).
MicroRNA quantification by real-time quantitative RT-PCR
SYBR green qRT-PCR assay was used for miRNA quantification
in plasma samples. In brief, 40 ng of plasma RNA containing
miRNA was polyadenylated by poly(A) polymerase and reverse
transcribed to cDNA using miScript Reverse Transcription kit
(Qiagen) according to the manufacturer’s instructions. Real-
time qPCR was performed using miScript SYBR Green PCR kit
(Qiagen) with the manufacturer provided miScript Universal
primer and the miRNA-specific forward primers in ABI PRISM
7900 Real-time PCR system (Applied Biosystems). The miRNA-
specific primer sequences were
c 59-ACGCAAATTCGTGAAGCGTT-39 for RNU6B
c 59-TAGCAGCACGTAAATATTGGCG-39 for miR-16
c 59-TATGGCTTTTCATTCCTATGTG-39 for miR-135b
c 59-ACTGCAGTGAAGGCACTTGT-39 for miR-17-3p
c 59-AGCTACATCTGGCTACTGGGTC-39 for miR-222
c 59-TATTGCACTTGTCCCGGCCTG-39 for miR-92
c 59-TTCAACGGGTATTTATTGAGCA-39 for miR-95
Sequences were designed based on the miRNA sequences
obtained from the miRBase database (http://microrna.sanger.
ac.uk/; accessed 22 April 2009). Each reaction was performed in
a final volume of 10 ml containing 2 ml of the cDNA, 0.5 mmol/l
of each primer and 16 SYBR Green PCR Master mix (Qiagen).
The amplification profile was: denaturation at 95uC for 15 min,
followed by 40 cycles of 94uC for 15 s, 55uC for 30 s and 70uC
for 30 s, in which fluorescence was acquired. At the end of the
PCR cycles, melting curve analyses were performed as well as
electrophoresis of the products on 3.5% agarose gels in order to
validate the specific generation of the expected PCR product.
Each sample was run in duplicates for analysis. The expression
levels of miRNAs were normalised to RNU6B.
Statistical analysis
The significance of plasma miRNA levels was determined by the
Mann–Whitney test, Wilcoxon test, the x2 test or Kruskal–
Wallis test where appropriate. The Spearman rank order
correlation test was used to examine correlation relationships
between the levels of the miRNA markers. The sensitivity and
specificity were calculated according to the standard formulas.
Multivariate logistic regression model was established and leave-
one-out cross-validation to find the best logistic model. Receiver
operating characteristic (ROC) curves were established for
discriminating patients with or without CRC. All p values are
two-sided and less than 0.05 was considered statistically
Table 2 The list of upregulated miRNAs (change .2-fold as a cut-off level) in plasma and biopsy samples of colorectal cancer (CRC) compared to
healthy controls, identified using real-time polymerase chain reaction-based miRNA profiling arrays
Plasma from 5 patients with CRC vs 5 healthy controls CRC vs adjacent normal biopsies from 5 patients with CRC
MicroRNA MirBase no
Average fold
change MicroRNA MirBase no Average fold change
miR-153 MIMAT0000439 9.81 miR-18a MIMAT0000072 4.21
miR-373 MIMAT0000726 9.60 miR-224 MIMAT0000280 3.69
miR-204 MIMAT0000265 9.20 miR-223 MIMAT0000279 3.54
miR-202 MIMAT0002811 9.15 miR-135b MIMAT0000758 3.12
miR-181c MIMAT0000258 8.10 miR-95 MIMAT0000094 2.87
miR-137 MIMAT0000429 7.39 miR-106a MIMAT0000103 2.81
miR-125a MIMAT0000443 7.38 miR-19a+b* MIMAT0000231, MIMAT0000263 2.75
miR-218 MIMAT0000275 6.65 miR-17-3p MIMAT0000071 2.72
miR-135b MIMAT0000758 6.54 miR-20a MIMAT0000462 2.58
miR-210 MIMAT0000267 5.85 miR-92 MIMAT0000092 2.38
miR-206 MIMAT0000462 5.76 miR-221 MIMAT0000077 2.24
miR-181d MIMAT0002821 5.54 miR-106b MIMAT0000680 2.23
miR-203 MIMAT0000264 5.37 miR-222 MIMAT0000279 2.18
miR-200b MIMAT0000318 5.35
miR-92 MIMAT0000092 4.45
miR-222 MIMAT0000279 4.58
miR-200a MIMAT0000682 4.45
miR-132 MIMAT0000426 4.34
miR-155 MIMAT0000646 4.29
miR-17-3p MIMAT0000071 4.17
miR-181b MIMAT0000257 3.92
miR-136 MIMAT0000448 3.88
miR-200c MIMAT0000617 3.73
miR-134 MIMAT0000447 3.39
miR-133a MIMAT0000427 3.37
miR-125b MIMAT0000423 3.32
miR-183 MIMAT0000261 3.10
miR-95 MIMAT0000094 3.04
miR-128b MIMAT0000676 3.00
miR-205 MIMAT0000266 2.93
The five markers upregulated in both plasma and CRC biopsies are given in bold type. *Co-detection of miRNA family members in this miRNA profiling array.
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significant. All statistical calculations were performed by the
SPSS software (version 13.0).
RESULTS
Patient characteristics
Patient characteristics and distribution of tumour stages are
summarised in table 1. A total of 245 participants including 130
patients with CRC, 75 healthy subjects, 20 patients with IBD
and 20 patients with GC were recruited. There were no
significant differences of age between patients with CRC (71
(SD 7.5) years), healthy controls (69 (SD 6.4) years), those with
IBD (71 (SD 7.7) years) and those with GC (68 (SD 6.7) years)
(p = 0.76, ANOVA). The sex distribution in the CRC group was
68:62 (male:female) and in the control group was 39:36
(p = 0.86, x2 test).
Identification of CRC-associated miRNAs in both plasma and
colorectal cancer tissue
In this marker discovery phase, a strategy for effective
identification of CRC-associated miRNAs in plasma was
developed. First, real-time PCR-based miRNA expression profil-
ing arrays were performed to identify differential expression
patterns of miRNAs in plasma between five patients with CRC
and five age-matched healthy normal controls. To rule out
plasma miRNAs predominantly derived from sources other than
CRC cells, differential expression patterns between cancerous
and adjacent non-cancerous tissues from the same five patients
with CRC were obtained by analysing their miRNA expression
profiles (supplementary table 1A,B). The differential expression
patterns between plasma and biopsy tissue samples were then
compared. Using 2-fold expression difference as a cut-off level,
five upregulated miRNAs (miR-17-3p, miR-135b, miR-222, miR-
92 and miR-95) in both plasma and colorectal cancer tissues in
the patients with CRC were identified (table 2).
Marker selection and validation on a small set of plasma
samples
To validate the five putative markers identified from the marker
discovery phase, qPCR assays were developed to quantify
miRNAs in plasma. In this qPCR, relative quantification was
applied and thus appropriate internal normalisation control was
required to normalise sample-to-sample variations. As no
consensus on the use of internal normalisation control in
plasma was defined for miRNA qPCR, expressions of U6 small
nuclear RNA (RNU6B) and miR-16 in plasma were evaluated.
Both have been proposed as the internal normalisation control
for microRNA quantification. Our data demonstrated that both
RNU6B and miR-16 were readily detectable in the plasma of all
controls and of patients with CRC. No significant difference
was observed in terms of Ct values of RNU6B (p = 0.47, Mann–
Whitney test) and miR-16 (p = 0.11, Mann–Whitney test)
between control and CRC samples (supplementary fig 1).
Although RNU6B shows less abundance than miR-16 in the
plasma, RNU6B was selected as the normalisation control as it
displayed expression levels of higher stability and less variability.
Using RNU6B as normalisation control, expression levels of
the five upregulated miRNAs were validated by qPCR on the 45
plasma samples (25 patients with CRC and 20 controls). Our
data indicated that detection rates of miR-135b, miR-222 and
miR-95 were,50% in both control and CRC plasma samples and
no significant difference was observed in their levels between
patients with CRC and controls (p = 0.29 for miR-135b, p = 0.18
Figure 1 MicroRNA selection and validation (Phase II) by quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis. Box plots of
plasma levels of (A) miR-17-3p and (B) miR-92 in healthy normal (N) subjects (n = 20) and patients with colorectal cancer (CRC) (n = 25). Expression
levels of the miRNAs (log10 scale at y-axis) are normalised to RNU6B. The lines inside the boxes denote the medians. The boxes mark the interval
between the 25th and 75th percentiles. The whiskers denote the interval between the 10th and 90th percentiles. Filled circles indicate data points outside
the 10th and 90th percentiles. Statistically significant differences were determined using Mann–Whitney tests. Changes of plasma levels of (C) miR-17-
3p and (D) miR-92 in patients with CRC (n = 10) before (pre-Op) and 7 days after (7 day post-Op) surgical removal of the tumour. Expression levels of
the miRNAs (log10 scale on the y-axis) are normalised to RNU6B. Statistically significant differences were determined using Wilcoxon tests.
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for miR-222, p = 0.53 for miR-95, Mann–Whitney test). Thus,
these three miRNAs were not chosen in further studies. The
remaining two miRNAs, miR-17-3p and miR-92, were detectable
in all 45 samples and significantly elevated in CRC plasma when
compared to controls (p,0.0005, Mann–Whitney test; fig 1A,B).
To verify whether miR-17-3p and miR-92 are associated with
CRC, their plasma levels were measured in an independent set
of 10 patients with CRC before and 7 days after surgical
removal of the tumours. It was found that the levels of both
miR-17-3p and miR-92 were significantly reduced in the post-
operative samples when compared to the pre-operative samples
(p,0.05, Wilcoxon test; fig 1C,D).
Independent large-scale validation on plasma samples
To further verify the discriminating power of the two miRNA
markers identified in phase II (marker selection and validation),
miR-17-3p and miR-92 were assessed on an independent group
of 140 plasma samples including 90 patients with CRC and 50
healthy controls (supplementary table 2A,B). Both miR-17-3p
and miR-92 were significantly elevated in plasma of patients
with CRC than those in controls (p,0.0001, Mann–Whitney
test; fig 2A,B). ROC curve analyses revealed that the plasma
levels of both miR-17-3p and miR-92 were useful biomarkers for
differentiating patients with CRC from controls with ROC
curve areas of 0.717 (95% confidence interval (CI), 0.63 to 0.80)
and 0.885 (95% CI, 0.83 to 0.94), respectively (fig 2C,D). At the
cut-off value of 3.6 for miR-17-3p (relative expression in
comparison to RNU6B snRNA), the sensitivity was 64% and
the specificity was 70%. At the cut-off value of 240 for miR-92
(relative expression in comparison to RNU6B snRNA), the
sensitivity was 89% and the specificity was 70%. Multivariate
logistic regression analysis showed that miR-92 was a potential
biomarker (p,0.0005) for CRC detection, but addition of miR-
17-3p could not improve the differentiation between patients
with CRC and controls, indicating the overlapping of the
diagnostic values of miR-92 and miR-17-3p. Spearman rank
correlation showed that plasma levels of miR-92 and miR-17-3p
were positively correlated (R2 = 0.63, p,0.0001; fig 3A). This
further supported the overlapping of the diagnostic values of miR-
92 and miR-17-3p. The odds ratio for cases with miR-92.240
being associated with cancer was 18.7 (95% CI, 7.6 to 45.6).
To rule out that elevation of plasma miR-92 level was simply
due to bowel inflammation or other gastrointestinal cancer,
plasma from 20 patients with IBD and 20 with GC was
included. Our results indicated that plasma miR-92 level in both
patients with IBD and those with GC is not significantly higher
than that in healthy controls (fig 3B). In fact, plasma miR-92
level in IBD cases is significantly lower than in healthy controls.
To examine whether the plasma miR-92 level may be associated
with stages of the disease, patients were stratified by TNM
staging. Of the 90 patients with CRC, miR-92 levels did not
vary significantly across the staging (p = 0.45, Kruskal–Wallis
test; fig 3C). However, significant differences were obtained
when individual tumour stage was compared with the controls,
(stage I, p,0.05; stage II, p,0.0001; stage III, p,0.0001; stage
IV, p,0.0001, Mann–Whitney test).
DISCUSSION
This is the first report on the quantitative assessment of plasma
miRNAs in patients with CRC. We identified significantly
elevated levels of miR-92 and miR-17-3p in the plasma of such
patients. Plasma miR-92 alone demonstrated as the best markers
for CRC prediction and yielded a ROC curve area of 88.5%. At a
cut-off of 240, the sensitivity was 89% and the specificity was
70% in discriminating CRC from control subjects. This makes
miR-92 a better marker than miR-17-3p as the latter has a lower
sensitivity. The odds ratio for the cases with miR-92 level .240
being associated with CRC was 18.7, which was much higher
than the odds ratio (7.6; 95% CI, 1.8 to 31.4) recently reported
for a positive first guaiac faecal occult blood test (FOBT).22
Thus, this finding compares favourably with one of the best
results using other non-invasive biomarkers such as FOBT for
the diagnosis of CRC.
Figure 2 Validation (Phase III) of miR-92
and miR-17-3p on an independent group
of plasma samples (n = 140). Scatter
plots of plasma levels of (A) miR-92 and
(B) miR-17-3p in healthy normal (N)
subjects (n = 50) and patients with
colorectal cancer (CRC) (n = 90).
Expression levels of the miRNAs (log10
scale on the y-axis) are normalised to
RNU6B. The line represents the mean
value. Statistically significant differences
were determined using Mann–Whitney
tests. Receiver operating characteristics
(ROC) curve analysis using (C) plasma
miR-17-3p and (D) plasma miR-92 for
discriminating CRC. Plasma miR-17-3p
yielded a ROC curve value of 71.7% (95%
confidence interval (CI), 0.633 to 0.800),
sensitivity of 64%, and specificity of 70%
in discriminating CRC. Plasma miR-92
yielded a ROC curve value of 88.5% (95%
CI, 0.828 to 0.942), sensitivity of 89%,
and specificity of 70% in discriminating
CRC.
Colorectal cancer
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In this study, we have also developed a systematic approach
to identify CRC-associated miRNAs in plasma by comparing
differential expression pattern between plasma and biopsies.
Using pre- and post-operative plasma samples, we confirmed
that elevation of plasma miR-92 and miR-17 is likely derived
from CRC as most patients have markedly reduced levels after
surgical resection of tumours. Intriguingly, the two upregulated
miRNAs (miR-17-3p and miR-92) in CRC are encoded by a miR-
17-92 gene cluster.4 The fact that both miR-92 and miR-17-3p
expression are upregulated in plasma may be due to the similar
regulatory mechanism. Indeed, the miR-17-92 cluster first
attracted attention following a series of observations linking
these miRNAs to cancer pathogenesis.23 24 The oncogenic role of
miR-17-92 cluster where miR-17 and miR-92 are located had
been reported in other cancers such as lymphoma,25 lung,26 27
and thyroid.28 Expression of miR-17-92 cluster promotes cell
proliferation, suppresses apoptosis of cancer cells, and induces
tumour angiogenesis.29
Since chronic inflammation is a risk factor for CRC, it may be
that elevated plasma miR-92 level in CRC is a feature of bowel
inflammation. Furthermore, to determine whether miR-92
elevation is CRC-specific, we examined plasma from patients
with IBD and GC. Importantly, we showed that miR-92
elevation is not associated with inflammation or other gastro-
intestinal cancer and most likely is CRC-related. It is not clear
why miR-92 is under-expressed in IBD cases. In the future, it is
worth studying the underlying mechanism of plasma miR-92
level reduction in a large sample of patients with IBD compared
to healthy controls. Elevation of plasma miR-92 level has not
only detected in advanced stages but also in early stages of
tumour, suggesting that this marker might be useful for early
detection of CRC. There was no difference in plasma miR-92
level in stage I to IV of the disease. Furthermore, we have not
been able to correlate the plasma miR-92 level with tumour
volume and metastatic status.
Notably, we demonstrated that plasma miRNA-based qPCR
assays can provide accurate screening methods for CRC. Our
finding that differential expression of a single miRNA in plasma
could discriminate CRC raises the possibility of using such
markers to develop a non-invasive and rapid diagnostic test for
CRC in the future. In comparison to the commonly employed
stool tests, a plasma test is more convenient as there is no
requirement for dietary restriction and meticulous collection of
stool samples. Furthermore, miRNA markers have several
advantages: (1) unlike screening for large numbers of mRNA
expression, a modest number of miRNAs might be sufficient to
differentiate cancers from normal; and (2) unlike plasma
mRNAs, miRNAs in plasma remain largely intact and have
been proven to be more stable for detection.16 19
Although our results are promising, there are several
limitations in this study. First, as the sample size is still small,
further validations of this marker in large cohorts and in
independent studies are necessary. Second, qPCR by the relative
quantification approach becomes less accurate if measuring
with low levels of miRNAs, in which they may not fall into the
linear range of the assay. Based on the Ct values of all samples,
we believe that miR-92 is not of low abundance in plasma, yet
absolute quantification approach with standard curve calibra-
tion would be preferable for further validation of our approach.
Third, although miR-92 elevation in plasma are likely to be
derived from CRC, it is uncertain whether this elevation is
specific for CRC, and whether it can be used to differentiate
sporadic from familial types of CRC. Thus, additional studies
will be needed to examine familial and sporadic cases. Fourth,
Figure 3 (A) Scatter plot of expression level correlation between miR-
92 and miR17-3p from the 140 plasma samples including 90 patients
with colorectal cancer (CRC) and 50 healthy controls. Positive correlation
was obtained by Spearman correlation, R2 = 0.625, p,0.0001. (B) Box
plot of plasma miR-92 level in healthy normal (N) subjects (n = 50),
patients with CRC (n = 90), patients with inflammatory bowel disease
(IBD) (n = 20) and patients with gastric cancer (GC) (n = 20). (C) Box
plot of plasma miR-92 level across stage. The box represents the
interquartile range and the line across the box indicates the median
value. Expression levels of the miRNAs (log10 scale on the y-axis) are
normalised to RNU6B. Statistically significant differences were
determined using Mann–Whitney tests.
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despite the significantly elevated levels of plasma miR-92 in
stage I of CRC, it is desirable to examine whether its plasma
level changes in patients suffering from adenoma with various
degree of dysplasia in the future. If plasma miR-92 can be used
for the detection of pre-malignant lesions such as adenoma, it
would add more value to use this marker for CRC prevention.
In conclusion, differentially expressed miRNAs in plasma of
patients with colorectal cancer have been reported in this study.
MicroRNA-92 has reasonable sensitivity for CRC detection and
compares favourably with the FOBT. This test, if validated in a
large-scale study, may be useful in future as a non-invasive
screening test for CRC.
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